ODM203 manufacturers
- ODM-203
-
- $36.00 / 2mg
-
2025-05-13
- CAS:1430723-35-5
- Min. Order:
- Purity: 99.85%
- Supply Ability: 10g
|
| Product Name: | ODM203 | | Synonyms: | ODM203;N-[2',4'-Difluoro-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl][1,1'-biphenyl]-3-yl]cyclopropanesulfonamide;Cyclopropanesulfonamide, N-[2',4'-difluoro-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl][1,1'-biphenyl]-3-yl]-;N-(2',4'-Difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1'-biphenyl]-3-yl)cyclopropanesulfonamide;anti-tumor immunity,ODM-203,FGFR,HUVEC,H1581,Inhibitor,cancer,Vascular endothelial growth factor receptor,SNU16,ODM203,ODM 203,RT4,Fibroblast growth factor receptor,VEGFR,inhibit;ODM-203, 10 mM in DMSO | | CAS: | 1430723-35-5 | | MF: | C26H21F2N5O2S | | MW: | 505.54 | | EINECS: | | | Product Categories: | | | Mol File: | 1430723-35-5.mol |  |
| | ODM203 Chemical Properties |
| Boiling point | 732.4±70.0 °C(Predicted) | | density | 1.48±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 66.67 mg/mL (131.88 mM; Need ultrasonic) | | form | A crystalline solid | | pka | 7.88±0.20(Predicted) | | color | White to yellow |
| | ODM203 Usage And Synthesis |
| Uses | ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment[1]. | | in vivo | ODM-203 (20, 40 mg/kg; p.o.; single daily for 21 days) inhibits FGFR phosphorylation and tumor growth in several FGFR-dependent xenografts by suppressing FGFR signaling in tumors[1].
ODM-203 (7, 20, 40 mg/kg; p.o.; single daily for 21 days) shows strong anti-tumor activity in a VEGFR-dependent angiogenic orthotopic syngenic model (Renca) and suppresses angiogenesis[1].
ODM-203 (20, 40 mg/kg; p.o.; single daily for 5 days) activates immune response in the tumor microenvironment[1]. | Animal Model: | Athymic Nude-Foxn1nu female mice (9-week-old; subcutaneous xenograft models)[1]. | | Dosage: | 20, 40 mg/kg | | Administration: | Oral administration; single daily for 21 days. | | Result: | Significantly inhibited tumour growth for 21 consecutive days.
Showed tumor growth inhibition (TGI) in RT4 xenografts was 37% and 92% with dosage of 20 and 40 mg/kg, respectively.
|
| Animal Model: | Male balb/c mice (8-week-old; orthotopic renca syngenic model)[1]. | | Dosage: | 7, 20, 40 mg/kg | | Administration: | Oral administration; single daily for 21 days. | | Result: | Showed tumor growth inhibition were 39%, 58% and 75% for dosage of 7, 20 and 40 mg/kg, respectively.
Inhibited formation of lung metastasis, and suppressed angiogenesis.
|
| Animal Model: | Male balb/c male mice (5 to 7-week-old; renca subcutaneous tumor model)[1]. | | Dosage: | 20, 40 mg/kg | | Administration: | Oral administration; single daily for 5 days. | | Result: | Resulted in an increase in the percentage of total and CD4 T cells.
Decreased the expression of immune check points PD-1 and PD-L1 and increased IFN-γ expression on both CD8 T cells and NK cells.
|
| | IC 50 | FGFR1: 11 nM (IC50); FGFR2: 16 nM (IC50); FGFR3: 6 nM (IC50); FGFR4: 35 nM (IC50); VEGFR1: 26 nM (IC50); VEGFR2: 9 nM (IC50); VEGFR3: 5 nM (IC50); DDR1: 6 nM (IC50); RET: 8 nM (IC50); SIK3: 23 nM (IC50); PDGFRa: 35 nM (IC50); MINK1: 41 nM (IC50); MAP4K4: 49 nM (IC50) | | References | [1] Holmstr?m TH, et al. ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity. Mol Cancer Ther. 2019 Jan;18(1):28-38. DOI:10.1158/1535-7163.MCT-18-0204 |
| | ODM203 Preparation Products And Raw materials |
|